Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

Biogen Idec has partnered with Google X, Google's business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), ...

S&P 500 component Biogen IDEC Inc reported net income above Wall Street’s expectations for the third quarter. Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge neighbors Biogen Idec Inc. and Alnylam ...

This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an ...

) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson's disease, ...

14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Ratings for Biogen (NASDAQ:BIIB) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their ...

Biogen Idec BIIB today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like ...

Jan 29 (Reuters) - Biogen Idec Inc on Wednesday said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera. The U.S. biotechnology company's net ...

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case ...